经导管主动脉瓣植入术后五年随访:症状性主动脉瓣狭窄
基于德国TAVI注册研究1378例患者(随访完整度95.4%),分析TAVI术后5年死亡率及预测因素。5年死亡率为59.1%,1年死亡率为21.8%。残余主动脉瓣反流≥II°、二尖瓣反流≥II°、肾功能衰竭等为独立预测因素,部分因素可能可干预。
要点
- TAVI术后5年死亡率为59.1%,1年死亡率为21.8%。
- 残余主动脉瓣反流≥II°与5年死亡风险独立相关(HR=1.52)。
- 女性性别与较低5年死亡风险独立相关(HR=0.66)。
核心结论
- TAVI术后5年死亡率为59.1%,部分预测因素如残余主动脉瓣反流、TAVI入路类型及合并二尖瓣反流可能可干预。
研究设计与样本
- 基于德国经导管主动脉瓣介入注册研究,纳入27家连续TAVI患者,共1444例,其中1378例随访至少4.5年(完整度95.4%),终点为5年生存,采用Cox回归分析风险因素。
主要发现
- 计算1年死亡率为21.8%,5年死亡率为59.1%。
- logistic EuroScore<20%患者5年生存率45.5%,20%-40%为34.5%,>40%为28.4%。
临床怎么用
- 对于接受TAVI的症状性主动脉瓣狭窄患者,应关注残余主动脉瓣反流、二尖瓣反流、肾功能衰竭、心房颤动、衰弱等可干预或可评估因素,以优化患者选择和术后管理。
局限性
- 数据来自早期TAVI经验,可能不完全反映当前实践;观察性注册研究,存在未测量混杂可能。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Transcatheter aortic valve implantation (TAVI) has been implemented into the care of elderly patients suffering from severe symptomatic aortic stenosis. However, data on long-term follow-up are sparse and predictors of long-term mortality need to be evaluated to better select patients. Therefore, we aimed to analyse predictors of 5-year mortality after TAVI. METHODS: We analysed data from the German Transcatheter Aortic Valve Interventions-Registry. Each of the 27 participating hospitals agreed to include all consecutive TAVI patients at their institution. Out of 1444 patients treated with TAVI, 1378 patients had a follow-up of at least 4.5 years (completeness 95.4%). Endpoint for this analysis was 5-year survival. Cox regression analysis was used to determine risk factors associated with this endpoint. RESULTS: Patients who died were compared with survivors. The two groups showed multiple differences in patient characteristics, indications for interventions, preinterventional, as well as interventional characteristics and postinterventional events. Calculated 1-year mortality was 21.8% and 5-year mortality 59.1%. A higher logistic EuroScore was associated with a lower 5-year survival, being 45.5% in patients with a logistic EuroScore of <20%, 34.5% in those with 20% to 40% and 28.4% in patients with a logistic EuroScore >40%. Cox proportional hazard analysis revealed the following independent predictors of 5-year mortality: female gender (HR =0.66, 95% CI 0.56 to 0.77, p<0.0001), renal failure (HR=1.43, 95% CI 1.22 to 1.69, p<0.0001), prior mitral regurgitation ≥II° (HR=1.42, 95% CI 1.21 to 1.65, p<0.0001), residual aortic regurgitation ≥II° (HR=1.52, 95% CI 1.24 to 1.85, p<0.0001), atrial fibrillation (HR=1.38, 95% CI 1.18 to 1.64, p=0.0001), low gradient aortic stenosis (HR=1.48, 95% CI 1.19 to 1.84, p=0.0004), prior decompensation (HR=1.32, 95% CI 1.13 to 1.54, p=0.0006), frailty (HR=1.31, 95% CI 1.09 to 1.58, p=0.004), surgical TAVI (HR=1.42, 95% CI 1.12 to 1.80, p=0.004), age (by year) (HR=1.02, 95% CI 1.01 to 1.03, p=0.006), prior myocardial infarction (HR=1.29, 95% CI 1.07 to 1.57, p=0.009), urgent TAVI (HR=1.25, 95% CI 1.04 to 51, p=0.020) and diabetes mellitus (HR=1.20, 95% CI 1.02 to 1.40, p=0.024). CONCLUSIONS: These data from the early TAVI experience show a 5-year mortality of 59.1%. Some of the predictors of 5-year mortality seem to be modifiable, such as residual aortic regurgitation, type of TAVI access route and concomitant mitral regurgitation.
引用
- Zahn R, Werner N, Gerckens U, et al. Five-year follow-up after transcatheter aortic valve implantation for symptomatic aortic stenosis. Heart. 2017. PMID: 28684438. doi:10.1136/heartjnl-2016-311004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。